This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2015 Feb:17:1.

doi: 10.1016/S1567-5688(15)50001-9.

New insights on ezetimibe. Introduction

Alberico L Catapano¹

Affiliations

PMID: 25659868
DOI: 10.1016/S1567-5688(15)50001-9

New insights on ezetimibe. Introduction

Alberico L Catapano. Atheroscler Suppl. 2015 Feb.

. 2015 Feb:17:1.

doi: 10.1016/S1567-5688(15)50001-9.

Author

Alberico L Catapano¹

Affiliation

¹ Institute of Pharmacological Sciences, University of Milan, Milan, Italy. Electronic address: alberico.catapano@unimi.it.

PMID: 25659868
DOI: 10.1016/S1567-5688(15)50001-9

No abstract available

PubMed Disclaimer

Similar articles

Effect of ezetimibe on cholesterol absorption and lipoprotein composition in diabetes and metabolic syndrome.
Federici M. Federici M. Atheroscler Suppl. 2015 Feb;17:17-22. doi: 10.1016/S1567-5688(15)50005-6. Atheroscler Suppl. 2015. PMID: 25659872 Review.
Model of intestinal chylomicron over-production and ezetimibe treatment: impact on the retention of cholesterol in arterial vessels.
Mangat R, Warnakula S, Wang Y, Russell JC, Uwiera R, Vine DF, Proctor SD. Mangat R, et al. Atheroscler Suppl. 2010 Jun;11(1):17-24. doi: 10.1016/j.atherosclerosissup.2010.04.043. Epub 2010 May 14. Atheroscler Suppl. 2010. PMID: 20471328 Review.
Ezetimibe therapy: mechanism of action and clinical update.
Phan BA, Dayspring TD, Toth PP. Phan BA, et al. Vasc Health Risk Manag. 2012;8:415-27. doi: 10.2147/VHRM.S33664. Epub 2012 Jul 3. Vasc Health Risk Manag. 2012. PMID: 22910633 Free PMC article. Review.
[Ezetimibe--intestinal cholesterol absorbtion inhibitor].
Pikto-Pietkiewicz W, Pasierski T. Pikto-Pietkiewicz W, et al. Kardiol Pol. 2006 Dec;64(12):1434-41. Kardiol Pol. 2006. PMID: 17206545 Review. Polish. No abstract available.
Ezetimibe, oxidized low density lipoprotein, Lp (a), and dyslipidemia.
Fonseca HA, Izar MC, Bianco HT, Fonseca FA. Fonseca HA, et al. J Atheroscler Thromb. 2010 Aug 31;17(8):888. doi: 10.5551/jat.5918. Epub 2010 Aug 10. J Atheroscler Thromb. 2010. PMID: 20702973 No abstract available.

See all similar articles

Cited by

Clinical practice guideline for the management of lipids in adults with diabetic kidney disease: abbreviated summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2024.
Zac-Varghese S, Mark P, Bain S, Banerjee D, Chowdhury TA, Dasgupta I, De P, Fogarty D, Frankel A, Goldet G, Karalliedde J, Mallik R, Montero R, Sharif A, Wahba M, Dhatariya K, McCafferty K, Lioudaki E, Winocour P. Zac-Varghese S, et al. BMC Nephrol. 2024 Jul 6;25(1):216. doi: 10.1186/s12882-024-03664-1. BMC Nephrol. 2024. PMID: 38971750 Free PMC article. Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science